Source: Pharmaceutical Business Review

Hengrui Therapeutics: Hengrui Therapeutics unveils $100m investment from HR Bio Holdings for global clinical development

Hengrui Therapeutics (HTI) has signed an agreement with HR Bio Holdings Limited, a joint venture between Jiangsu Hengrui Medicine Co. Ltd. (JHM) and an undisclosed blue chip investment firm, regarding a $100 million investment in HTI.

Read full article »

Top Competitors or Alternatives

Looks like nobody has added any competitors for Hengrui Therapeutics yet.

Missing a competitor? Contribute!

Est. Annual Revenue
$6.3M
Agree?
Est. Employees
28
Agree?
Adam Zong's photo - President & CEO of Hengrui Therapeutics

President & CEO

Adam Zong

CEO Approval Rating

70/100

Read more